Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy and safety profile of the two strategies in C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Medicine 2022-11, Vol.11 (22), p.4134-4145
Hauptverfasser: Zhang, Yuchen, Liu, Panpan, Cai, Jun, Jing, Hongmei, Zou, Liqun, Huang, Huiqiang, Wu, Yuanbin, Li, Wenyu, Zhong, Liye, Jin, Xueli, Ye, Xu, Feng, Ru, Zhang, Huilai, Zhang, Liling, Lin, Lie, Sun, Xiuhua, Tian, Yuyang, Xia, Zhongjun, Li, Zhiming, Huang, He, Xia, Yi, Cai, Qingqing
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy and safety profile of the two strategies in Chinese patients with R/R MCL remain unclarified. Methods In the present study, data of 121 R/R MCL patients who received either ibrutinib monotherapy (N = 68) or ibrutinib combination therapy (N = 53) in 13 medical centers in China were retrospectively reviewed. Results With a median follow‐up of 20.5 months, the overall response rate was 60.3% versus 84.9% (p = 0.003), complete remission rate was 16.2% versus 43.4% (p
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.4765